Fascin expression is inversely correlated with breast cancer metastasis suppressor 1 and predicts a worse survival outcome in node-negative breast cancer patients

被引:17
|
作者
Lee, Hye Jin [1 ]
An, Hee Jung [1 ]
Kim, Tae Hoen [1 ]
Kim, Gwangil [1 ]
Kang, Haeyoun [1 ]
Heo, Jin Hyung [1 ]
Kwon, Ah-Young [1 ]
Kim, Sewha [1 ]
机构
[1] CHA Univ, CHA Bundang Med Ctr, Dept Pathol, 59 Yatap Ro, Seongnam Si 13496, Gyeonggi Do, South Korea
来源
JOURNAL OF CANCER | 2017年 / 8卷 / 16期
关键词
breast cancer; fascin; breast cancer metastasis suppressor 1; immunohistochemistry; AGGRESSIVE CLINICAL-COURSE; CARCINOMA METASTASIS; ACTIN CYTOSKELETON; OVARIAN-CARCINOMA; BRMS1; PROTEIN; CELLS; MIGRATION; MOTILITY; MARKER;
D O I
10.7150/jca.22046
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Fascin is an actin-bundling protein that promotes cancer cell migration and invasion. By contrast, breast cancer metastasis suppressor 1 (BRMS1) inhibits cancer metastasis by targeting multiple steps of the metastatic cascade. We evaluated whether expression patterns of fascin and BRMS1 correlate with clinicopathological features and patient outcome. Methods: Immunohistochemistry for fascin and BRMS1 was performed using a tissue microarray constructed from 183 human breast cancer tissues. Fascin expression determined by the proportion of stained tumor cells (0: 0-5%, 1: 6-25%, 2: 26-50%, 3: 51-75%, or 4: >75%) and staining intensity (0: negative, 1: weak, 2: moderate, or 3: strong) were multiplied and defined as negative (0-3) or positive (4-12). BRMS1 expression was scored separately based on nuclear and cytoplasmic staining intensity (0: negative, 1: weak, 2: moderate, 3: strong). We obtained the BRMS1 H score by summing the nuclear and cytoplasmic scores and defined it as negative (0-2) or positive (3-6). Results: Expression of BRMS1 showed a significant inverse correlation with that of fascin. Fascin(+) tumors were significantly associated with no lymph node metastasis, higher histological and higher nuclear grade, ER/PR/HER2 negativity, and triple-negative subtype (all ps < 0.05). These clinicopathological differences showed the same trend in a comparison of fascin(-)/BRMS1(+) and fascin(+)/BRMS1(-) tumors. Negative or weak BRMS1 cytoplasmic expression was significantly associated with shorter disease-free survival (DFS; p = 0.043). Fascin positivity was significantly associated with shorter DFS (p = 0.005) and overall survival (p = 0.020) when analyses were confined to node-negative patients. Conclusions: This study confirms an inverse correlation between expression of fascin and expression of BRMS1 using a quite large cohort of human breast cancer tissues. Fascin alone or combined with BRMS1 was a worse prognostic marker, particularly in node-negative breast cancer patients.
引用
收藏
页码:3122 / 3129
页数:8
相关论文
共 50 条
  • [41] CHEMOTHERAPY FOR NODE-NEGATIVE BREAST-CANCER
    JONES, SE
    CANCER INVESTIGATION, 1986, 4 (05) : 501 - 501
  • [42] Adjuvant Docetaxel for Node-Negative Breast Cancer
    Venniyoor, Ajit
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (10): : 976 - 977
  • [43] Inflammatory cells in node-negative breast cancer
    Lofdahl, Britta
    Ahlin, Cecilia
    Holmqvist, Marit
    Holmberg, Lars
    Zhou, Wenjing
    Fjallskog, Marie-Louise
    Amini, Rose-Marie
    ACTA ONCOLOGICA, 2012, 51 (05) : 680 - 686
  • [44] THERAPEUTIC MANAGEMENT OF NODE-NEGATIVE BREAST CANCER
    Ioanid, N.
    Miron, L.
    Terinte, C.
    Alexa, T.
    Panuta, A.
    Scripcariu, D. V.
    Ioanid, N. S.
    Scripcariu, V.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 713 - 713
  • [45] A New Look at Node-Negative Breast Cancer
    Harbeck, Nadia
    Thomssen, Christoph
    ONCOLOGIST, 2010, 15 : 29 - 38
  • [46] Expression patterns of claudins in patients with triple-negative breast cancer are associated with nodal metastasis and worse outcome
    Katayama, Ayaka
    Handa, Tadashi
    Komatsu, Kei
    Togo, Maria
    Horiguchi, Jun
    Nishiyama, Masahiko
    Oyama, Tetsunari
    PATHOLOGY INTERNATIONAL, 2017, 67 (08) : 404 - 413
  • [47] A New Look at Node-Negative Breast Cancer
    Harbeck, Nadia
    Thomssen, Christoph
    ONCOLOGIST, 2011, 16 : 51 - 60
  • [48] VEGF and radiotherapy in node-negative breast cancer
    Speirs V.
    Breast Cancer Research, 2 (1)
  • [49] TREATMENT OF NODE-NEGATIVE BREAST-CANCER
    LONG, D
    AMERICAN FAMILY PHYSICIAN, 1991, 44 (02) : 448 - 448
  • [50] Influence of internal mammary node irradiation on long-term outcome and contralateral breast cancer incidence in node-negative breast cancer patients
    Courdi, Adel
    Chamorey, Emmanuel
    Ferrero, Jean-Marc
    Hannoun-Levi, Jean-Michel
    RADIOTHERAPY AND ONCOLOGY, 2013, 108 (02) : 259 - 265